ACRO Biomedical is a biotech company well-known in the international biomedical industry which develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine.

ACRO has adopted a comprehensive development in the field of regenerative medicine, ranging from biomaterials to products for application. The main product is the collagen-based biomaterial, and it has broken new ground in product application; moving ACRO toward a more professional business with great influence in human tissue engineering and regenerative medicine.

In order to realize the impossible for human kind, ACRO Biomedical used its proprietary supercritical CO₂ extraction technology to extract highlybiocompatible biomaterials, and performed world’s first successful corneal transplantation in Chihuahua Bunny using ACRO cornea graft in early October, 2016. Two years later, human clinical trials are about to be conducted in Tri-Service General Hospital, Taipei Veterans General Hospital, Kaohsiung Veterans General Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital. Due to its excellent biotechnology, ACRO Biomedical and Tri-Service General Hospital signed a memorandum of understanding for the placement in the Innovation Incubation Center in March, 2019.

ACRO Biomedical has taken the lead in the industry to successfully develop various Class II and Class III medical device products for regenerative medicine, including collagen matrix for wound care, collagen membrane, collagen dental bone graft and bone graft in various forms, cartilage graft, collagen ophthalmic matrix, and collagen implant.

Commercial Times: ACRO Biomedical Realizing the Impossible for the Human Kind